^
    TNFRSF8 positive
    Cutaneous T-cell Lymphoma
    brentuximab vedotin
    Sensitive: A1 - Approval
    No biomarker
    Cutaneous T-cell Lymphoma
    bexarotene oral
    Sensitive: A1 - Approval
    No biomarker
    Cutaneous T-cell Lymphoma
    vorinostat
    Sensitive: A1 - Approval
    IL2RA expression
    Cutaneous T-cell Lymphoma
    denileukin diftitox
    Sensitive: A1 - Approval
    No biomarker
    Cutaneous T-cell Lymphoma
    denileukin diftitox
    Sensitive: A1 - Approval
    No biomarker
    Cutaneous T-cell Lymphoma
    RP6530
    Sensitive: B - Late Trials
    TNFRSF8 expression
    Cutaneous T-cell Lymphoma
    brentuximab vedotin
    Sensitive: C1 - Off-label
    PD-L1 underexpression
    Cutaneous T-cell Lymphoma
    durvalumab + lenalidomide
    Sensitive: C3 – Early Trials
    RPS6 underexpression
    Cutaneous T-cell Lymphoma
    ruxolitinib
    Sensitive: C3 – Early Trials
    ICOS underexpression
    Cutaneous T-cell Lymphoma
    durvalumab
    Sensitive: C3 – Early Trials
    PD-1 overexpression
    Cutaneous T-cell Lymphoma
    pembrolizumab
    Sensitive: C3 – Early Trials
    CD70 expression
    Cutaneous T-cell Lymphoma
    ARGX-110
    Sensitive: C3 – Early Trials